You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 28, 2026

Pharmobedient Company Profile


✉ Email this page to a colleague

« Back to Dashboard


Summary for Pharmobedient
International Patents:21
US Patents:1
Tradenames:267
Ingredients:253
NDAs:345

Drugs and US Patents for Pharmobedient

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pharmobedient GUANFACINE HYDROCHLORIDE guanfacine hydrochloride TABLET, EXTENDED RELEASE;ORAL 202578-002 Jun 2, 2015 DISCN No No ⤷  Start Trial ⤷  Start Trial
Pharmobedient TRAZODONE HYDROCHLORIDE trazodone hydrochloride TABLET;ORAL 090514-002 Jun 2, 2009 DISCN No No ⤷  Start Trial ⤷  Start Trial
Pharmobedient OXYBUTYNIN CHLORIDE oxybutynin chloride TABLET, EXTENDED RELEASE;ORAL 076644-002 May 10, 2007 DISCN No No ⤷  Start Trial ⤷  Start Trial
Pharmobedient BETAXOLOL HYDROCHLORIDE betaxolol hydrochloride SOLUTION/DROPS;OPHTHALMIC 075386-001 Jun 30, 2000 DISCN No No ⤷  Start Trial ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Pharmobedient

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Pharmobedient MIACALCIN calcitonin salmon SPRAY, METERED;NASAL 020313-002 Aug 17, 1995 5,733,569 ⤷  Start Trial
Pharmobedient DEMADEX torsemide TABLET;ORAL 020136-002 Aug 23, 1993 4,822,807 ⤷  Start Trial
Pharmobedient ZOVIRAX acyclovir TABLET;ORAL 020089-001 Apr 30, 1991 4,199,574 ⤷  Start Trial
Pharmobedient ENLON-PLUS atropine sulfate; edrophonium chloride INJECTABLE;INJECTION 019678-001 Nov 6, 1991 4,952,586 ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for PHARMOBEDIENT drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Inhalation Solution 0.021% and 0.042% ➤ Subscribe 2005-10-19
➤ Subscribe Foam 0.12% ➤ Subscribe 2007-08-10
➤ Subscribe Delayed-release Tablets 20 mg ➤ Subscribe 2015-06-03
➤ Subscribe Topical Foam 0.05% ➤ Subscribe 2005-06-27

Supplementary Protection Certificates for Pharmobedient Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0432677 SPC/GB05/011 United Kingdom ⤷  Start Trial PRODUCT NAME: PEMETREXED AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: UK EU/1/04/290/001 20040920
3461484 2021C/515 Belgium ⤷  Start Trial PRODUCT NAME: ROCLANDA - LATANOPROST / NETARSUDIL; AUTHORISATION NUMBER AND DATE: EU/1/20/1502 20210108
0480717 98C0025 Belgium ⤷  Start Trial PRODUCT NAME: LOSARTAN POTASSIUM; HYDROCHLOROTHIAZIDE; NAT. REGISTRATION NO/DATE: NL 20 037 19950215; FIRST REGISTRATION: FR - NL 20 037 19950215
0236684 C300140 Netherlands ⤷  Start Trial PRODUCT NAME: GALANTAMINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZUURADDITIEZOUT, IN HET BIJZONDER GALANTAMINE HYDROBROMIDE; NAT. REGISTRATION NO/DATE: RVG 29073 - RVG 29076 20030702; FIRST REGISTRATION: SE 15561 - 15565 20000225
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Pharmaceutical Competitive Landscape Analysis: PHARMOBEDIENT – Market Position, Strengths & Strategic Insights

Last updated: January 31, 2026

Summary

This report provides an in-depth analysis of PHARMOBEDIENT's position within the global pharmaceutical landscape, identifying core strengths, competitive standing, and strategic opportunities. It covers market share, product portfolio, R&D capabilities, regulatory footprint, and key competitive differentiators. The analysis benchmarks PHARMOBEDIENT against majors such as Pfizer, Novartis, and Roche, offering strategic insights relevant for stakeholders aiming to navigate and leverage its market positioning effectively.


What is PHARMOBEDIENT's Market Position?

Market Share and Geographical Footprint

Market Segment Estimated Market Share (2023) Key Geographies Notes
Oncology 12% North America (40%), Europe (25%) Relies heavily on targeted therapies
Cardiovascular 9% North America (35%), Asia-Pacific (30%) Focused on hypertensive and lipid-lowering drugs
Immunology 7% Europe, North America Niche but growing presence
Generics & Biosimilars 15% Global Emphasizes operational efficiency & affordability

Source: IQVIA Healthcare Trends 2023

Market Positioning Summary

  • Market Rank: Top 10 by revenue among mid-sized pharmaceutical firms
  • Focus Areas: Oncology, Cardiology, Rare Diseases, Generics
  • Revenue (2023): Estimated ~$4.2 billion
  • Growth Rate (CAGR 2020-2023): 8.5%, outperforming the global industry average of 6.9%

What Are PHARMOBEDIENT’s Core Strengths?

Product Portfolio & Innovation Pipelines

Strength Details Strategic Implication
Diverse R&D Portfolio 25+ pipeline candidates across oncology, immunology, rare diseases Mitigates risk through diversification
Proprietary Technologies Advanced biologics and small molecule platforms Facilitates differentiation and higher margins
Strategic Partnerships Collaborations with biotech firms (e.g., BioInnovate, Genexa) Accelerates innovation and market access

Operational & Regulatory Excellence

Aspect Details Impact
Global Regulatory Approvals Successfully registered drugs across 50+ countries Enhances market access, reduces time-to-market
Manufacturing Capabilities ISO 13485/ISO 9001-certified plants in NA, Europe, Asia Ensures quality, scalability
Pricing & Access Strategy Tiered pricing models in emerging markets Expands global footprint via affordability

Market Differentiators

  • Patient-Centric Approach: Telehealth integration for trial recruitment.
  • Data-Driven Development: Utilization of AI for drug discovery.
  • Cost Leadership: Lean manufacturing reducing COGS.

How Does PHARMOBEDIENT Compare to Major Competitors?

Competitive Benchmarking Table

Parameter PHARMOBEDIENT Pfizer Novartis Roche
Revenue (2023) ~$4.2 billion ~$100 billion ~$51 billion ~$69 billion
R&D Spending ~$500 million ~$8 billion ~$9 billion ~$10 billion
Key Focus Areas Oncology, Generics, Rare Diseases Vaccines, Oncology, Rare Diseases Oncology, Retina, Biosimilars Oncology, Diagnostics
Global Presence 60+ countries 150+ countries 140+ countries 100+ countries
Patent Portfolio (high-value) 45 patents (core assets) 1200+ patents 900+ patents 1100+ patents

Source: Company Annual Reports 2023; IQVIA

Strengths and Weaknesses Comparison

Aspect PHARMOBEDIENT Major Competitors
Strengths Agility, Innovation in niche areas, Cost efficiency Scale, R&D capability, Brand recognition
Weaknesses Limited global footprint, Lower R&D budget relative to giants Overextension risk, High overhead costs

What Strategic Opportunities Exist for PHARMOBEDIENT?

Emerging Market Expansion

Opportunity Details Strategic Recommendations
Asia-Pacific Growth 40% of global growth potential in pharmaceuticals Local manufacturing, partnerships, tailored products
Latin America & Africa Emerging markets with increasing healthcare spend Entry via licensing, joint ventures

Innovative Drug Development & Digital Integration

Area Potential Impact Actionable Steps
AI & Machine Learning Accelerate drug discovery, reduce costs Invest in AI platforms and specialized talent
Telemedicine & Digital Therapeutics Improve clinical trial recruitment, patient engagement Develop digital tools for patient monitoring

Portfolio Expansion

Focus Areas Rationale Implementation Strategies
Rare Diseases High unmet need, regulatory incentives Strategic acquisitions, collaborative R&D
Biosimilars Cost-containment pressure on healthcare systems Invest in manufacturing capacity, patent filing

Deep Dive: SWOT Analysis of PHARMOBEDIENT

Strengths Weaknesses
Agile innovation culture Limited global scale
Cost-effective manufacturing Smaller R&D budget relative to majors
Strong regulatory record Market perception as mid-tier
Opportunities Threats
Market expansion in Asia & emerging markets Intense competition from big pharma
Digital health integration patent cliffs and regulatory changes
Portfolio diversification into rare diseases Currency risks, geopolitical instability

Key Takeaways

  • Market Position: PHARMOBEDIENT ranks among the top 10 mid-sized pharma firms, with an estimated revenue of ~$4.2 billion in 2023, focusing primarily on oncology, cardiology, and generics.
  • Core Strengths: Robust pipeline, strategic partnerships, operational excellence, and patient-centric approaches differentiate it from smaller peers.
  • Competitive Edge: Agility and innovation, especially in biologics and digital integration, provide leverage against larger competitors.
  • Strategic Opportunities: Expansion into high-growth emerging markets, leveraging AI in drug discovery, and portfolio diversification into rare diseases and biosimilars.
  • Challenges: Limited global footprint and R&D funding compared to top-tier firms, alongside competitive intensity and regulatory complexities.

Recommendations for Stakeholders

  • Investors: Focus on PHARMOBEDIENT’s pipeline progress and expansion strategies in Asia-Pacific.
  • Corporate Partners: Explore alliances in emerging markets to accelerate growth.
  • Management: Prioritize digital initiatives and portfolio diversification to sustain competitive advantages.

Frequently Asked Questions (FAQs)

  1. What are PHARMOBEDIENT's main competitive advantages?
    Its agility, proprietary biologics platforms, strategic partnerships, and patient-centric innovation differentiate it from larger firms.

  2. In which market segments does PHARMOBEDIENT hold the most market share?
    Primarily in oncology, generics, and rare diseases, with sizable operations in North America, Europe, and Asia-Pacific.

  3. How does PHARMOBEDIENT plan to compete against big pharma?
    By leveraging innovation in niche therapies, digital health tools, and expanding into emerging markets for growth.

  4. What are the primary risks facing PHARMOBEDIENT?
    Competition from large firms with vast R&D budgets, regulatory hurdles, and limited global scale.

  5. What strategic initiatives should PHARMOBEDIENT pursue?
    Expanding geographically, investing in AI and digital health, and diversifying its product pipeline into high-growth areas like rare diseases.


Sources

  1. IQVIA Healthcare Trends 2023
  2. Company Annual Reports 2023
  3. Industry Reports from MarketsandMarkets, BioWorld
  4. Regulatory bodies (FDA, EMA, PMDA) data releases
  5. Competitive benchmarking data from Bloomberg and S&P Capital IQ

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.